Anti-LTB IgG Avidity Indices from a Pediatric ETEC Vaccine Trial in Zambia

60 Zambian children aged 6–23 months received three doses of the ETVAX® vaccine with dmLT adjuvant. Plasma samples from three time points were analyzed to calculate IgG avidity indices for CS3 and LTB antigens, assessing antibody quality. The dataset, published by Cynthia Mubanga, contains results from this immunogenicity study conducted in an endemic setting.

Use Cases

• Analyzing the relationship between antibody avidity and titre-defined naïve status based on ROC analysis results.
• Studying vaccine-induced antibody responses in an endemic pediatric population based on the cohort description.
• Comparing baseline and post-vaccination avidity indices for CS3 and LTB antigens over three time points.
• Investigating functional naivety in children with detectable titres but low avidity, as described in the results.

Strengths

• Includes data from 60 pediatric participants across three defined time points (Day 1, 22, 97).
• Measures both anti-CS3 and anti-LTB IgG avidity indices, providing a dual-antigen perspective.
• Applies two classification methods (titre-based and avidity-defined) for naïve status.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 15.1 KB, indicating limited scope.

Provenance

Source

figshare, author Cynthia Mubanga.

Collection Method

Plasma samples from a clinical trial were analyzed by limiting antigen dilution ELISA to calculate avidity indices.

Time Range

Samples collected at baseline (Day 1), Day 22, and Day 97.

Freshness

Last updated 2026-05-15 17:25:33; freshness should be verified.

Geography

Zambia.